MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$7,793K
EPS
-$0.47
Unit: Thousand (K) dollars

Income Statement
2026-03-31
Research and development expenses
2,405
General and administrative expenses
8,672
Loss from operating activities
-11,077
Foreign exchange loss
-1
Change in fair value of derivative warrant liabilities
-900
Interest and other income, net
685
Total other income, net
1,584
Loss before income tax benefit
-9,493
Income tax benefit
-1,700
Net loss
-7,793
Basic EPS
-0.47
Diluted EPS
-0.47
Basic Average Shares
16,510,632
Diluted Average Shares
16,510,632
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net loss-$7,793K Income tax benefit-$1,700K Change in fair value ofderivative warrant...-$900K Interest and otherincome, net$685K Loss before incometax benefit-$9,493K Total other income,net$1,584K Foreign exchange loss-$1K Loss from operatingactivities-$11,077K General andadministrative expenses$8,672K Research and developmentexpenses$2,405K

Grace Therapeutics, Inc. (GRCE)

Grace Therapeutics, Inc. (GRCE)